Clinical Trials Browser

Phase 2 × Melanoma × mirdametinib × Clear all

NCT07237100 2025-11-19

Mirdametinib in Patients With Advanced NF1-mutant Melanoma

Phase 2 Recruiting

CNSDermatologic

Melanoma, Neurofibromatoses